Clinical trials: Uncontrolled Hypertension
Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a…
- Trial name
- TARDIA (NCT01079195)
- Where
- 898 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 15,436 people
- Sponsor
- Abbott
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between…
- Trial name
- BaxAsia (NCT06344104)
- Testing
- Baxdrostat
- Where
- 93 sites in Argentina, Australia and 9 more
- Volunteers
- 326 people
- Sponsor
- AstraZeneca
Open Angle Glaucoma
MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
The study will evaluate the efficacy and safety of MINIject 636 and IOP lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery.
- Trial name
- NCT03374553
- Testing
- MINI DO636, MINI SO636
- Where
- 3 sites in Colombia, India and 1 more
- Volunteers
- 52 people
- Sponsor
- iSTAR Medical
Hypertension
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not…
- Trial name
- NCT00700271
- Testing
- Amlodipine, Valsartan
- Where
- 2 sites in France, Tunisia
- Volunteers
- 478 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients.
- Trial name
- NCT01200407
- Testing
- Amlodipine + Olmesartan medoxomil
- Where
- 51 sites in Philippines
- Volunteers
- 615 people
- Sponsor
- Pfizer
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Uncontrolled Hypertension
Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
This is a prospective, single-arm, non-randomized and open label feasibility study. The study is intended to evaluate safety and efficacy of multi-electrode radiofrequency renal denervation in patients with uncontrolled…
- Trial name
- NCT01699529
- Testing
- Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 50 people
- Sponsor
- Medtronic Vascular
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Glaucoma
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle…
- Trial name
- NCT01230736
- Testing
- Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Uncontrolled Hypertension
EuroNetrod HTN OFF-Med Study of Renal Denervation With NetrodTM Six-electrode Radiofrequency RDN System
This randomized controlled investigation aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes…
- Trial name
- EuroNetrod (NCT06722651)
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Switzerland
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Open Angle Glaucoma, Ocular Hypertension
MINIject Global Long-Term Follow-up Study
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
- Trial name
- STAR-GLOBAL (NCT04524416)
- Testing
- Minimally invasive glaucoma surgery (MIGS)
- Where
- 9 sites in Colombia, France and 4 more
- Volunteers
- 116 people
- Sponsor
- iSTAR Medical
Uncontrolled Hypertension
EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension
The purpose of this observational study is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension in clinical routine practice.
- Trial name
- NCT01996033
- Where
- 12 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Hypertension Resistant to Conventional Therapy
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product.
- Trial name
- NCT02690909
- Testing
- Redy™ Renal Denervation System
- Where
- 10 sites in Belgium, Germany and 6 more
- Volunteers
- 55 people
- Sponsor
- Renal Dynamics GmbH
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Uncontrolled Hypertension
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
- Trial name
- NCT07051603
- Testing
- SAL0140
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Uncontrolled Hypertension
Effect of the MobiusHD® in Renal Hemodialysis Subjects With Uncontrolled Hypertension
This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and benefit of the MobiusHD® system in renal hemodialysis subjects with uncontrolled hypertension.
- Trial name
- HD (NCT05352425)
- Testing
- MobiusHD
- Sponsor
- Vascular Dynamics, Inc.